Cole Wayant; Matthew J. Page, PhD; Matt Vassar, PhD
free access
JAMA Oncol. 2019;5(11):1550-1555. doi:10.1001/jamaoncol.2019.2564
This cross-sectional study evaluates the reproducibility of research practices in oncology systematic reviews with meta-analyses cited by the National Comprehensive Cancer Network guidelines for the treatment of cancer by site.
Peter Schmid, FRCP, PhD; Matthias Zaiss, MD; Catherine Harper-Wynne, MD; et al.
open access
JAMA Oncol. 2019;5(11):1556-1564. doi:10.1001/jamaoncol.2019.2526
This open-label phase 2 randomized clinical trial evaluates the safety and efficacy of vistusertib in combination with fulvestrant compared with fulvestrant alone or fulvestrant plus everolimus for women with hormone receptor鈥損ositive metastatic breast cancer.
Carlos Fernández-Martos, MD; Carles Pericay, MD, PhD; Ferran Losa, MD, PhD; et al.
free access
JAMA Oncol. 2019;5(11):1566-1573. doi:10.1001/jamaoncol.2019.2294
This phase 2 randomized clinical trial evaluates the effect of modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX) induction chemotherapy with or without aflibercept before chemoradiotherapy and total mesorectal excision surgery in patients with high-risk, locally advanced rectal adenocarcinoma.
Takayuki Yoshino, MD, PhD; Takeharu Yamanaka, PhD; Eiji Oki, MD, PhD; et al.
open access
JAMA Oncol. 2019;5(11):1574-1581. doi:10.1001/jamaoncol.2019.2572
This phase 3 randomized clinical trial evaluates the outcomes and the incidence of peripheral sensory neuropathy of 3 months vs 6 months of adjuvant oxaliplatin-based chemotherapy for colon cancer.
Ghassan K. Abou-Alfa, MD; Qian Shi, PhD; Jennifer J. Knox, MD; et al.
free access
JAMA Oncol. 2019;5(11):1582-1588. doi:10.1001/jamaoncol.2019.2792
This phase 3 randomized clinical trial follows treatment of advanced hepatocellular cancer with doxorubicin plus sorafenib to determine if it improves overall survival in patients vs treatment with sorafenib alone.
Fei Wang, MD, PhD; Xiang Shu, PhD; Ingrid Meszoely, MD; et al.
free access
JAMA Oncol. 2019;5(11):1589-1596. doi:10.1001/jamaoncol.2019.2803
This cohort study analyzes data from the National Cancer Database to evaluate the factors associated with higher mortality rates among men with breast cancer compared with women with breast cancer during the first few months after diagnosis.
Dawei Chen, MD; Hari Menon, BS; Vivek Verma, MD; et al.
free access
JAMA Oncol. 2019;5(11):1597-1604. doi:10.1001/jamaoncol.2019.2809
This phase 1/2 single-arm trial examined toxic effects, local control, and overall survival rates after chemoradiotherapy with a simultaneous integrated boost of radiotherapy dose to the gross tumor and nodal disease for patients with unresectable locally advanced esophageal cancer.
Kathryn H. Schmitz, PhD, MPH; Andrea B. Troxel, ScD; Lorraine T. Dean, ScD; et al.
free access
JAMA Oncol. 2019;5(11):1605-1613. doi:10.1001/jamaoncol.2019.2109
This randomized clinical trial assesses whether home-based exercise, weight loss, or a combination of home-based exercise and weight loss have an effect on breast cancer鈥搑elated lymphedema outcomes among overweight breast cancer survivors.
Oscar Arrieta, MD, MSc; Feliciano Barrón, MD; Miguel-Ángel Salinas Padilla, MD; et al.
free access
online only
JAMA Oncol. 2019;5(11):e192553. doi:10.1001/jamaoncol.2019.2553
This randomized clinical trial assesses the progression-free survival in patients with advanced lung adenocarcinoma who received treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) plus metformin compared with those who received EGFR-TKIs alone.
Jessica K. Roydhouse, PhD; Daniel L. Suzman, MD; Laurel A. Menapace, MD; et al.
free access
online only
JAMA Oncol. 2019;5(11):e192971. doi:10.1001/jamaoncol.2019.2971
This study analyzes the pattern of opioid use among patients with metastatic prostate cancer enrolled in clinical trials conducted in 46 countries.